The biotech company, Enzymatica, is to offer a new product line, veterinary products, and is planning for sales in the North American market. The first products will be launched in mid-2014, and are expected to generate sales for Enzymatica during the second half of the year.
Over the past few years, Enzymatica has devoted considerable time and resources to the research and development of veterinary products. As a result, the company is now able to start a new product line, with products for animals, aimed at dental health and dermatology. The products will treat gingivitis and plaque in small animals, and eczema and skin irritation in animals such as dogs, cats and horses.
The company has recently concluded a pilot study in which 33 dogs were treated for plaque and gingivitis at a veterinary clinic in Washington DC. The eight-week course of treatment produced excellent results.
”After treatment, the dogs showed a significant reduction in both gum inflammation and plaque”, says Mats Clarsund, Research and Development Manager at Enzymatica.
As part of its veterinary product venture, Enzymatica has established a subsidiary in the USA, Enzymatica North America Inc. Enzymatica North America Inc. will be responsible for the production and sale of the products in the USA and Canada. The primary target group is veterinarians. In the USA alone, there are around 44,000 veterinary clinics. The total pet market in the USA is estimated to be worth around $55.5 billion, with an annual growth rate of 5 percent. Sales of veterinary products are expected to reach $13.2 billion(1). The projected launch date for Enzymatica’s products is mid-2014.
”The development of our new veterinary product line and the investment in the North American market are strategically important for Enzymatica, not least as the beginning of our international operation”, says Michael Edelborg Christensen, CEO of Enzymatica.
For more information on Enzymatica, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ), +46(0)768-14 41 66, email@example.com
Mats Clarsund, Research and Development Manager, Enzymatica AB (publ), +46(0)725-730 980 firstname.lastname@example.org
(1) http://www.americanpetproducts.org/press_industrytrends.asp, (Supplies/OTC medicine estimated 2013)